THE SHORT VERSION
- A dated notice is different from live news coverage.
- Read the original source for its full scope.
- Price retrieval dates and editorial dates describe different work.
29 January 2026: pancreatitis warnings strengthened
The MHRA updated warnings about potentially severe acute pancreatitis with GLP-1 and dual GLP-1/GIP medicines. Our pancreatitis guide explains the symptom pattern that needs urgent assessment and what to tell the treating team. The original safety notice gives the regulatory context.
5 February 2026: semaglutide and sudden vision changes
The MHRA published advice about the very rare risk of NAION with semaglutide. Sudden loss of sight or rapidly worsening vision needs urgent eye assessment. Read our vision-change guide and the MHRA notice for the scope of this warning.
How to use dates on this site
These are selected notices, not a complete live news feed. A content update records an editorial change to a guide. A price retrieval date records a data collection attempt that produced the displayed snapshot. Neither means an independent clinician reviewed the page.
For a question about your own treatment, contact your prescriber rather than waiting for a website update. To flag an inaccurate page, use Contact and corrections with the page address and original source.
Sources you can check
- MHRA: strengthened pancreatitis warnings, 29 January 2026
- MHRA: semaglutide and NAION, 5 February 2026
Content updated . This is general information, not individual medical advice or a claim of independent clinical review. Read the linked source and the leaflet supplied with your medicine for the full context. Suggest a correction.